Curi Bio Acquires Dana Solutions

July 23, 2020

Curi Bio, a Seattle-based developer of human iPSC platforms for drug discovery, has acquired Dana Solutions to integrate Dana's AI/ML platforms (PhenoLearn, Pulse, PhenoTox) into Curi's human cell- and tissue-based discovery and safety-testing offerings. The deal (terms undisclosed) will allow Curi to offer combined predictive human iPSC-derived models and AI-enabled phenotypic data insights and will continue a prior FDA-funded collaboration to validate PhenoTox.

Buyers
Curi Bio
Targets
Dana Solutions
Industry
Biotechnology
Location
California, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.